Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Operating Expenses: 2014-2024

Historic Operating Expenses for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $150.9 million.

  • Viking Therapeutics' Operating Expenses rose 169.62% to $98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.8 million, marking a year-over-year increase of 105.15%. This contributed to the annual value of $150.9 million for FY2024, which is 49.68% up from last year.
  • As of FY2024, Viking Therapeutics' Operating Expenses stood at $150.9 million, which was up 49.68% from $100.8 million recorded in FY2023.
  • Viking Therapeutics' 5-year Operating Expenses high stood at $150.9 million for FY2024, and its period low was $42.7 million during FY2020.
  • Moreover, its 3-year median value for Operating Expenses was $100.8 million (2023), whereas its average is $107.4 million.
  • Data for Viking Therapeutics' Operating Expenses shows a peak YoY spiked of 49.68% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Viking Therapeutics' Operating Expenses stood at $42.7 million in 2020, then spiked by 30.52% to $55.7 million in 2021, then rose by 26.35% to $70.4 million in 2022, then surged by 43.31% to $100.8 million in 2023, then soared by 49.68% to $150.9 million in 2024.